This report describes the clinical, laboratory, and epidemiological findings on 27 cases of Mayaro virus (MV) disease, an emerging mosquito-borne viral illness that is endemic in rural areas of tropical South America. MV disease is a nonfatal, dengue-like illness characterized by fever, chills, headache, eye pain, generalized myalgia, arthralgia, diarrhea, vomiting, and rash of 3 -5 days' duration. Severe joint pain is a prominent feature of this illness; the arthralgia sometimes persists for months and can be quite incapacitating. Cases of two visitors from the United States, who developed MV disease during visits to eastern Peru, are reported. MV disease and dengue are difficult to differentiate clinically.
Mayaro virus (MV) disease is an acute febrile illness of several small outbreaks of MV disease have been described in residents of rural communities in northern Brazil [11, 12 ] and 3 -5 days' duration that is characterized by headache, retroorbital pain, arthralgia, myalgia, vomiting, diarrhea, and rash in eastern Bolivia [13] , human cases of the disease are generally sporadic and occur most commonly in persons in recent contact [1] . MV is a member of the genus Alphavirus, family Togaviridae. Like most of the other alphaviruses, MV is transmitted to with humid, tropical forests [1] . This finding is probably due to the fact that mosquitoes of the Neotropical genus Haemagohumans by the bite of infected mosquitoes. MV is related to chikungunya, o'nyong-nyong, Ross River, Barmah Forest, and gus are the presumed principal vectors [1, 7, 14] and that most members of this genus are forest-dwelling [15] . Sindbis viruses, five other alphaviruses that produce a similar clinical illness in infected people [2 -7] .
MV disease is a zoonotic illness. Although MV, its mosquito vectors, and its wild vertebrate hosts have undoubtedly coex-MV was first isolated from sick forest workers in Trinidad in 1954 [6] . Subsequently, isolates were recovered from huisted in Neotropical forests for a long time, recent demographic and land use changes in tropical South America appear to be mans, wild vertebrates, and mosquitoes in Colombia, Brazil, Suriname, Guyana, French Guiana, Peru, and Bolivia [1, 6 - altering the frequency of this endemic disease in people. As the human population in the region increases and as more 9]. Serological studies [1, 7 -10] indicate that MV infection is relatively common in human populations living in rural areas people enter forested areas for work and for recreation, the number of persons at risk of MV infection is increasing. Furof northern South America and the Amazon Basin. Although thermore, with the reappearance of dengue in much of South America and the initiation of a hemisphere-wide measles eradication program, surveillance of febrile exanthems in the region has intensified. Consequently, more cases of MV disease are CID 1999; 28 (January) with Ç300,000 people that is located in the northeastern AmaThe 14 other patients with MV disease were seen at health facilities elsewhere in Peru (figure 1). Blood samples from zon Region of Peru in Loreto Department ( figure 1) The immune ascitic fluids specific to eastern equine encephalitis virus, VEE virus, and MV were used in the IFAT at a 1:50 dilution. Preliminary studies indicated that MV could be differentiated from the other two alphaviruses by IFAT at this dilution. Six of the MV isolates, including isolates from patients 1 and 2 (see case reports), were confirmed by the plaque reduction neutralization test (PRNT) [21] . The isolate from patient 2 was also sequenced (see below).
Sequence Analysis
The nucleotide sequence of the MV isolate from patient 2 was determined and compared with the available sequences of the and RNA extracted from the viral pellet with use of Trizol (Life had received yellow fever, hepatitis A and B, rabies, and typhoid vaccines. During her visit, she had taken mefloquine as Techologies, Grand Island, NY) as previously described [22] . The copy DNA was synthesized with use of a poly T oligonucleotide prophylaxis for malaria. Physical examination at the time of admission revealed a thin primer (T 25 V-Mlu; 5TTACGAATTCACGCGCT 25 V-3) designed to anneal to the viral polyadenylation sequence. PCR amfemale in some distress because of headache, but no other physical abnormalities were found. Multiple insect bites were noted on plification was performed with use of the T 25 V-Mlu primer with a forward primer (a 10247A; 5-TACCCNTTYATGTGGGG-3) the feet, lower legs, and thighs. Initial blood studies showed a hemoglobin level of 13.4 g/dL, hematocrit of 38.2%, platelet to generate a fragment containing most of the E1 gene and the complete 3 noncoding region as described previously [22] . The count of 124,000/mm 3 , and leukocyte count of 3,200/mm 3 , with 65% neutrophils and 4% band cells. Urinalysis was unremarkable, resulting PCR product was cloned into the PCR2.1 vector (Invitrogen, Carlsbad, CA) and was sequenced with use of the plasas was a chest roentgenogram. Examination of a blood smear for malaria and a serological test for Salmonella were both negative. mid-specific T7 promoter and m13 reverse primers (Gibco BRL, Gaitnersburg, MD). The nucleotide sequence was aligned with A blood sample was obtained at the time of admission; a serum sample was frozen and submitted to the CDC for diagnostic testing alphavirus sequences determined previously and obtained from GenBank (Bethesda, MD) with use of the GAP and PILEUP for dengue. At the time of admission to the hospital, the patient was programs in the GCG package [23] .
given intravenous fluids for her dehydration and propoxyphene napsylate and acetaminophen tablets for pain. The following
Serological Assays
day, the patient was afebrile, and her headache and joint pains had diminished; she was discharged at her request. On the All acute-and convalescent-phase serum samples were sixth day after the onset of symptoms, a diffuse papular rash screened initially at a dilution of 1:100 for IgM antibodies to developed on her arms, legs, and buttocks. MV was subse-MV and VEE virus by using an IgM antibody capture ELISA quently isolated from the acute-phase serum specimen submit-(MACEIA) [24] . Reactive samples were subsequently retested ted to the CDC. MV-specific IgM as well as neutralizing antiat serial dilutions of 1:200 through 1:102,400 to determine end bodies were absent from the first serum sample, but both point titers. Several of the serum samples were also titrated by antibodies were present in a second (convalescent-phase) serum EIA for IgG antibodies to MV and VEE virus.
sample obtained 20 days after the onset of the illness (table Serum samples from patients 1 and 2 were also examined 1). The patient had a complete recovery, although joint pain for neutralizing antibodies to MV and VEE, chikungunya, Ross and stiffness persisted for several months in her hands and River, and Getah viruses by PRNT [21] at twofold dilutions knees; effusions were also noted in her knees and joints of the from 1:10 to 1:640. The highest serum dilution at which §80% hands. plaque reduction occurred was considered the end point.
Case 2 Diagnostic Criteria
A 29-year-old American female graduate student, who was A confirmed case of MV disease was defined as an acute trapping small mammals in a forest reserve near Iquitos, develdengue-like illness and isolation of MV. A presumptive diagnosis of MV disease was made if the patient had a compatible antibodies to MV and VEE virus were ú1:400 and õ1:100, respectively, in a single serum sample. with a presumptive diagnosis of dengue fever because of con-* Reciprocal of highest serum dilution at which §80% plaque reduction occurred (no antibody, õ1:10).
tinued fever and dehydration. Before visiting Peru, the patient / 9c5e$$ja05
12-30-98 15:55:19 cidal UC: CID oped fever, headache, generalized myalgia, weakness, and diarwere diagnosed. MV was isolated from acute-phase serum samples from 21 (77.8%) of these patients (confirmed cases); the rhea on 14 August 1997. These symptoms continued for the next 2 days. The patient did not consult a physician and continremaining six cases (presumptive) were diagnosed by serology. Of the 24 patients for whom demographic data were collected, ued her field work; however, she noted that it became increasingly difficult to walk because of severe myalgia and arthralgia.
13 were females, and 11 were males. The ages of these patients ranged from 9 to 65 years (figure 2). Occupational information On the fourth day of her illness she reported that she ''could hardly move'' because of severe joint pains and spent the entire was available for 17 of the patients and was as follows: general laborer, 4 patients; agricultural worker, 3; housekeeper, 5; studay in bed. On the fifth day (18 August 1997), she felt better and was visited by a public health nurse who noted a maculodent, 2; soldier, 1; biologist, 1; and missionary, 1. The cases of MV disease were sporadic ( figure 3 ) and ocpapular rash on her neck and arms, made a presumptive diagnosis of dengue fever, and obtained a blood sample for diagnostic curred over a wide geographic area of the country ( figure 1) . Twelve of the 27 cases were detected during prospective surstudies.
MV was subsequently isolated from that sample at the U.S. veillance of patients with febrile illness in Iquitos. The remaining 15 cases were detected fortuitously by the isolation Naval Medical Research Unit Institute Detachment's laboratory in Lima. MV-specific IgM, IgG, and neutralizing antibodies of MV from serum samples from patients with suspected cases of dengue or yellow fever that were submitted to our laboratory also were demonstrated in convalescent-phase serum samples obtained at various intervals after her illness (tables 1 and 2).
for confirmation. To our knowledge, this is the first report of MV disease in Peru. However, MV isolations from people in The patient's symptoms gradually abated; she resumed work on 23 August 1997, although stiffness, joint pains (wrists and other South American countries have been reported previously [1, 6, 11 -13] under similar circumstances; sporadic cases were ankles), and fatigability persisted for about 2 months.
The patient was taking mefloquine as prophylaxis for malaria detected coincidentally during the investigation of other disease outbreaks. Collectively, these results and the relatively high at the time of her illness in Peru. Before her departure from the United States to Peru in June 1997, the patient had received prevalence of antibodies to MV that was observed among persons living in rural areas of tropical South America [1, 7, 9, hepatitis A and B, yellow fever, and VEE (TC-83 live-attenuated) vaccines [25] . Several days after receiving the VEE vac-10] suggest that MV disease is much more common than is generally reported. cine in early May 1997, she had symptoms of low-grade fever, chills, headache, and myalgia, which lasted 24 -36 hours. AnalThe prevalence of presenting symptoms and signs in 22 of the patients with MV disease who were included in our study ysis of a postvaccination blood sample obtained on 27 May 1997 indicated that she had seroconverted; a titer of neutralizis shown in table 3. The symptomatology was similar to that reported in previous clinical descriptions of the disease [1, 6, ing antibody to VEE virus of 1:160 was detected in her serum at that time (table 1). The latter result was confirmed at the 11, 12]. The relatively low prevalence of rash (31.9%) in our series can probably be explained by the fact that most of the U.S. Army Medical Research Institute of Infectious Diseases.
patients were seen in the early phase of their illness, while they still had viremia. Pinheiro et al. [12] reported that the rash Results and Discussion associated with MV disease usually appears about the fifth day of illness, at the time that the viremia ends and humoral During the period from April 1995 to April 1998, a total of antibodies first appear. Patients 1 and 2 in our study were 27 cases of MV disease in persons living or working in Peru observed over a longer period, and their rashes appeared on the sixth and fifth day of the illness, respectively. Dengue was initially suspected in a number of the patients inoculated only into mosquito cells. The number of infected prototype strain of MV (TRVL 4675), while the next closest serum samples inoculated into both cell lines was small; thererelatives, Bebaru virus (strain MM 2354) and Una virus (strain fore, it was not possible to accurately compare the relative BeAr13136), had only a 60% -66% nucleotide identity [7] . sensitivity of the two culture systems. MV produced a marked
Results of serological studies of acute-and convalescentcytopathic effect in Vero cells, thus revealing viral infection.
phase serum samples from patients 1 and 2 are shown in tables In contrast, infection in the mosquito cells was often inapparent, 1 and 2. Patient 1 seroconverted, and the titer of neutralizing although occasionally syncytium formation was observed [28] .
antibody to MV was 1:80 in a second serum sample taken 20 Six of the MV isolates, including the strains recovered from days after the onset of her illness on 1 March 1996 (table 1) . patients 1 and 2, were confirmed by PRNT. In addition, the IgM antibody capture ELISA of the same sample gave a posi-MV isolate from patient 2 (designated as IQT-4235) was setive reaction up to a dilution of 1:1,600 (data not shown). quenced. The PCR product, encompassing the E1 gene and
The serological results for patient 2 were more complicated the 3 noncoding region, was analyzed by comparison of the because she previously had received live-attenuated VEE vacnucleotide sequence with those of other known alphaviruses.
cine. In a serum sample obtained in February 1996, before Pairwise comparisons and phylogenetic analysis by using parsi-VEE vaccination and MV infection, there were no detectable mony showed that IQT-4235 was most closely related to vineutralizing antibodies to any of the five alphaviruses (MV and ruses within the antigenic complex of the Semliki Forest virus. VEE, chikungunya, Ross River, and Getah viruses) tested (table The isolate IQT-4235 had a 95% nucleotide identity with the 1). In a serum sample obtained on 27 May 1997, about 3 weeks after she had received VEE vaccine, the titer of neutralizing antibody to VEE virus was 1:160, but no antibodies to the other four viruses were detected (titer, õ1:10). 
